Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	12.20B +10.5%
Revenue (ttm)	759.63M +13.6%
Net Income	-23.81M
EPS	-0.06
Shares Out	405.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,537,364
Open	29.63
Previous Close	29.87
Day's Range	28.60 - 30.36
52-Week Range	20.41 - 44.90
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 436
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2025, SHA:688319's revenue was 704.16 million, an increase of 19.58% compared to the previous year's 588.86 million. Earnings were 22.26 million, an increase of 7.24%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error